| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 4938 | 2014 |
| Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ... The Lancet 387 (10027), 1551-1560, 2016 | 969 | 2016 |
| NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, ... Nature medicine 21 (8), 914-921, 2015 | 968 | 2015 |
| Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma J Krejcik, T Casneuf, IS Nijhof, B Verbist, J Bald, T Plesner, K Syed, K Liu, ... Blood, The Journal of the American Society of Hematology 128 (3), 384-394, 2016 | 927 | 2016 |
| A monoclonal gammopathy precedes multiple myeloma in most patients BM Weiss, J Abadie, P Verma, RS Howard, WM Kuehl Blood, The Journal of the American Society of Hematology 113 (22), 5418-5422, 2009 | 700 | 2009 |
| Chimeric antigen receptor T cells against CD19 for multiple myeloma AL Garfall, MV Maus, WT Hwang, SF Lacey, YD Mahnke, JJ Melenhorst, ... New England Journal of Medicine 373 (11), 1040-1047, 2015 | 633 | 2015 |
| B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma AD Cohen, AL Garfall, EA Stadtmauer, JJ Melenhorst, SF Lacey, ... The Journal of clinical investigation 129 (6), 2210-2221, 2019 | 626 | 2019 |
| Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma A Chari, A Suvannasankha, JW Fay, B Arnulf, JL Kaufman, ... Blood, The Journal of the American Society of Hematology 130 (8), 974-981, 2017 | 494 | 2017 |
| Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma SZ Usmani, BM Weiss, T Plesner, NJ Bahlis, A Belch, S Lonial, ... Blood, The Journal of the American Society of Hematology 128 (1), 37-44, 2016 | 492 | 2016 |
| The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group N Leung, F Bridoux, V Batuman, A Chaidos, P Cockwell, VD D’Agati, ... Nature Reviews Nephrology 15 (1), 45-59, 2019 | 456 | 2019 |
| Racial disparities in incidence and outcome in multiple myeloma: a population-based study AJ Waxman, PJ Mink, SS Devesa, WF Anderson, BM Weiss, ... Blood, The Journal of the American Society of Hematology 116 (25), 5501-5506, 2010 | 446 | 2010 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 434 | 2016 |
| How I treat monoclonal gammopathy of renal significance (MGRS) JP Fermand, F Bridoux, RA Kyle, E Kastritis, BM Weiss, MA Cook, ... Blood, The Journal of the American Society of Hematology 122 (22), 3583-3590, 2013 | 359 | 2013 |
| Daratumumab-based treatment for immunoglobulin light-chain amyloidosis E Kastritis, G Palladini, MC Minnema, AD Wechalekar, A Jaccard, HC Lee, ... New England Journal of Medicine 385 (1), 46-58, 2021 | 352 | 2021 |
| Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis O Landgren, BM Weiss Leukemia 23 (10), 1691-1697, 2009 | 293 | 2009 |
| Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis AJ Waxman, S Clasen, WT Hwang, A Garfall, DT Vogl, J Carver, ... JAMA oncology 4 (3), e174519-e174519, 2018 | 225 | 2018 |
| First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction MA Gertz, H Landau, RL Comenzo, D Seldin, B Weiss, J Zonder, G Merlini, ... Journal of Clinical Oncology 34 (10), 1097, 2016 | 219 | 2016 |
| Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study A D'Souza, A Dispenzieri, B Wirk, MJ Zhang, J Huang, MA Gertz, RA Kyle, ... Journal of Clinical Oncology 33 (32), 3741-3749, 2015 | 205 | 2015 |
| Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study SF Huntington, BM Weiss, DT Vogl, AD Cohen, AL Garfall, PA Mangan, ... The Lancet Haematology 2 (10), e408-e416, 2015 | 202 | 2015 |
| Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA G Palladini, E Kastritis, MS Maurer, J Zonder, MC Minnema, ... Blood, The Journal of the American Society of Hematology 136 (1), 71-80, 2020 | 200 | 2020 |
